SCHEMBL11166256

SCHEMBL11166256

CCCCCCC(C)(C)c1ccc([C@H]2CCC[C@@H](O)C2)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 16/20 0.75
CNR1 P21554 4/20 0.62
TSHR P16473 2/20 0.62
ALDH1A1 P00352 1/20 0.62
TP53 P04637 1/20 0.62
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
ALOX15 P16050 1/20 0.62
NFKB1 P19838 1/20 0.62
MAPK1 P28482 1/20 0.62
THPO P40225 1/20 0.62
HSD17B10 Q99714 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
MEN1 O00255 1/20 0.62
NPC1 O15118 1/20 0.62
GMNN O75496 1/20 0.62
LMNA P02545 1/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C9 P11712 1/20 0.62
APEX1 P27695 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11165640 1.00 CNR2 (0.75) CNR2CNR1TSHRALDH1A1TP53
SCHEMBL11160652 1.00 CNR2 (0.75) CNR2CNR1TSHRALDH1A1TP53
SCHEMBL11156383 1.00 CNR2 (0.75) CNR2CNR1TSHRALDH1A1TP53
SCHEMBL11170587 1.00 CNR2 (0.75) CNR2CNR1TSHRALDH1A1TP53
SCHEMBL11167646 1.00 CNR2 (0.75) CNR2CNR1TSHRALDH1A1TP53
SCHEMBL11171046 1.00 CNR2 (0.75) CNR2CNR1TSHRALDH1A1TP53
SCHEMBL11160655 1.00 CNR2 (0.75) CNR2CNR1TSHRALDH1A1TP53
SCHEMBL11166255 1.00 CNR2 (0.75) CNR2CNR1TSHRALDH1A1TP53
SCHEMBL15478743 1.00 CNR2 (0.75) CNR2CNR1TSHRALDH1A1TP53
SCHEMBL11156389 1.00 CNR2 (0.75) CNR2CNR1TSHRALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220370650-A1 FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF VYRIPHARM ENTERPRISES, INC. 2022-11-24 US claimed
US-20220305147-A1 SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES VYRIPHARM ENTERPRISES, INC. 2022-09-29 US claimed
US-11554184-B2 Synthetic cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases VYRIPHARM ENTERPRISES, INC. (US) 2023-01-17 US disclosed
US-20220370650-A1 FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF VYRIPHARM ENTERPRISES, INC. 2022-11-24 US disclosed
US-20220305147-A1 SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES VYRIPHARM ENTERPRISES, INC. 2022-09-29 US disclosed
WO-2020232350-A1 ASSAYS FOR SYNTHETIC CANNABINOIDS THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2020-11-19 WO disclosed
US-20180021247-A1 TOPICAL COMPOSITIONS COMPRISING HYDROXY ACIDS AND CANNABINOIDS FOR SKIN CARE Kannalnnovations LLC (US) 2018-01-25 US disclosed
US-20180021247-A1 TOPICAL COMPOSITIONS COMPRISING HYDROXY ACIDS AND CANNABINOIDS FOR SKIN CARE Kannalnnovations LLC (US) 2018-01-25 US disclosed
US-20170042791-A1 TOPICAL COMPOSITIONS COMPRISING HYDROXY ACIDS AND CANNABINOIDS FOR SKIN CARE KannaInnovations LLC (US) 2017-02-16 US disclosed
US-20170042791-A1 TOPICAL COMPOSITIONS COMPRISING HYDROXY ACIDS AND CANNABINOIDS FOR SKIN CARE KannaInnovations LLC (US) 2017-02-16 US disclosed
US-9347961-B2 Test kit for the quantitative determination of narcotic drugs CHIRON AS (NO) 2016-05-24 US disclosed
EP-2722669-A1 Method and device for detecting illegal drugs Securetec Detektions-Systeme AG (DE) 2014-04-23 EP disclosed
EP-2698385-A1 Detection of synthetic cannabinoids Randox Laboratories Ltd. (GB) 2014-02-19 EP disclosed
EP-2687854-A1 Test kit for the quantitative determination of narcotic drugs Chiron AS (NO) 2014-01-22 EP disclosed
US-8575230-B2 Environment-friendly antifoulants for the prevention of biofouling UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH (US) 2013-11-05 US disclosed
US-20120208213-A1 Detection of Synthetic Cannabinoids RANDOX LABORATORIES LIMITED (GB) 2012-08-16 US disclosed
US-20100256256-A1 ENVIRONMENT-FRIENDLY ANTIFOULANTS FOR THE PREVENTION OF BIOFOULING THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2010-10-07 US disclosed
EP-0860168-B1 Use of central cannbinoid receptor CB1 agonists BAYER HEALTHCARE AG (DE) 2007-08-08 EP disclosed
US-4391827-A 3-(2-Hydroxy-4-(substituted)phenyl)-cycloalkanone and cycloalkanol analgesic agents and intermediates therefor PFIZER INC. (US) 1983-07-05 US disclosed
US-4306097-A 3-[2-Hydroxy-4-(substituted)phenyl]-cycloalkanol analgesic agents PFIZER INC. (US) 1981-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11554184-B2 Synthetic cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases CNR2, CNR1, FAAH CNR2 1/4885CNR1 2/4885TSHR 3314/4885
US-20170042791-A1 TOPICAL COMPOSITIONS COMPRISING HYDROXY ACIDS AND CANNABINOIDS FOR SKIN CARE CNR2, CNR1, HCAR3 CNR2 1/4885CNR1 2/4885TSHR 4646/4885
US-20220370650-A1 FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF ADA, SLC29A1, SLC29A2 CNR2 4580/4885CNR1 4154/4885TSHR 3198/4885
US-20100256256-A1 ENVIRONMENT-FRIENDLY ANTIFOULANTS FOR THE PREVENTION OF BIOFOULING TRPV1, CNR2, CNR1 CNR2 2/4885CNR1 3/4885TSHR 3611/4885
US-20120208213-A1 Detection of Synthetic Cannabinoids CNR2, CNR1, FAAH CNR2 1/4885CNR1 2/4885TSHR 1782/4885
US-20220305147-A1 SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES CNR2, CNR1, FAAH CNR2 1/4885CNR1 2/4885TSHR 3314/4885
US-20180021247-A1 TOPICAL COMPOSITIONS COMPRISING HYDROXY ACIDS AND CANNABINOIDS FOR SKIN CARE CNR2, CNR1, HCAR3 CNR2 1/4885CNR1 2/4885TSHR 4646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.